deferiprone has been researched along with Glaucoma in 3 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 7.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| " The oral iron chelator deferiprone (DFP) is protective against retinal degenerations associated with oxidative stress." | 3.96 | Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, F | 1 |
| Peng, J | 1 |
| Zhang, E | 1 |
| Ji, D | 1 |
| Gao, Z | 1 |
| Tang, Y | 1 |
| Yao, X | 1 |
| Xia, X | 1 |
| Cui, QN | 1 |
| Bargoud, AR | 1 |
| Ross, AG | 1 |
| Song, Y | 1 |
| Dunaief, JL | 1 |
| Rosignol, I | 1 |
| Villarejo-Zori, B | 1 |
| Teresak, P | 1 |
| Sierra-Filardi, E | 1 |
| Pereiro, X | 1 |
| RodrÃguez-Muela, N | 1 |
| Vecino, E | 1 |
| Vieira, HLA | 1 |
| Bell, K | 1 |
| Boya, P | 1 |
3 other studies available for deferiprone and Glaucoma
| Article | Year |
|---|---|
Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma.
Topics: Animals; Deferiprone; Disease Models, Animal; Ferroptosis; Glaucoma; Homeostasis; Humans; Intraocula | 2023 |
Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma.
Topics: Administration, Oral; Animals; Deferiprone; Disease Models, Animal; Female; Glaucoma; Iron Chelating | 2020 |
The
Topics: Animals; Cell Survival; Cells, Cultured; Deferiprone; Disease Models, Animal; Genes, Reporter; Glauc | 2020 |